Investigational drug · Phase 2
HGT-1110
Also called: Recombinant human arylsulfatase A
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metachromatic Leukodystrophy (MLD).
Phase 2Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "HGT-1110"
First trial start
2013
May 23, 2013
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HGT-1110", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metachromatic Leukodystrophy (MLD)
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "HGT-1110" as an intervention, largest first.
ShireTakeda (TAK)
NCT03771898 · 36 participants · Start May 13, 2019 · Primary completion Mar 8, 2023
Drug: SHP611 · For: Metachromatic Leukodystrophy (MLD)
Sites: Torrance, California; Aurora, Colorado; Atlanta, Georgia · 30 sites in all
ShireTakeda (TAK)
NCT01510028 · 24 participants · Start Feb 2, 2012 · Primary completion Jan 20, 2017
Drug: Recombinant human arylsulfatase A · For: Metachromatic Leukodystrophy (MLD)
Sites: Westmead, Australia; Copenhagen, Denmark; Le Kremlin-Bicêtre, France · 5 sites in all
ShireTakeda (TAK)
NCT01887938 · 24 participants · Start May 23, 2013 · Primary completion Feb 13, 2026
Drug: HGT-1110 · For: Metachromatic Leukodystrophy (MLD)
Sites: Westmead, Australia; Porto Alegre, Brazil; Brno, Czechia · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The effect of intrathecal recombinant arylsulfatase A therapy on structural brain magnetic resonance imaging in children with metachromatic leukodystrophy.
Groeschel S, Beerepoot S, Amedick LB, et al. · J Inherit Metab Dis 2024
- Effects of sulfatide on peripheral nerves in metachromatic leukodystrophy.
Farah MH, Dali CÍ, Groeschel S, et al. · Ann Clin Transl Neurol 2024
- Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: Results from a phase 1/2 clinical trial.
Í Dali C, Sevin C, Krägeloh-Mann I, et al. · Mol Genet Metab 2020
- Pharmacokinetic Modeling of Intrathecally Administered Recombinant Human Arylsulfatase A (TAK-611) in Children With Metachromatic Leukodystrophy.
Troy S, Wasilewski M, Beusmans J, et al. · Clin Pharmacol Ther 2020
- Measurement of recombinant human arylsulfatase A and leukocyte sulfatase activities by analytical isotachophoresis.
Pajarola S, Weißenberg C, Baysal F, et al. · J Chromatogr B Analyt Technol Biomed Life Sci 2019
- Nonclinical comparability studies of recombinant human arylsulfatase A addressing manufacturing process changes.
Wright T, Li A, Lotterhand J, et al. · PLoS One 2018
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Takeda.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.